Qianjiang Yongan Pharmaceutical Co Ltd
SZSE:002365
Intrinsic Value
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the research, development, production and sales of taurine products. [ Read More ]
The intrinsic value of one
Qianjiang Yongan Pharmaceutical Co Ltd
stock under the Base Case scenario is
7.47
CNY.
Compared to the current market price of 6.9 CNY,
Qianjiang Yongan Pharmaceutical Co Ltd
is
Undervalued by 8%.
Qianjiang Yongan Pharmaceutical Co Ltd's market capitalization is 2B CNY.
Qianjiang Yongan Pharmaceutical Co Ltd stock price is 6.9 CNY.
Qianjiang Yongan Pharmaceutical Co Ltd stock price (6.9 CNY) is 8% less than its Intrinsic Value (7.47 CNY).
Qianjiang Yongan Pharmaceutical Co Ltd stock price (6.9 CNY) is 26% less than its DCF Value (9.32 CNY). Open DCF Valuation
Qianjiang Yongan Pharmaceutical Co Ltd stock (5.61 CNY) is 19% less than its price (6.9 CNY). Open Relative Valuation
Qianjiang Yongan Pharmaceutical Co Ltd has upside potential of 174% compared to the average analyst price target.
Open Wall St Estimates
Qianjiang Yongan Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Qianjiang Yongan Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Qianjiang Yongan Pharmaceutical Co Ltd's Revenue has been falling by 3% per year for the last 3 years.
Qianjiang Yongan Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 6% to 1%.
Qianjiang Yongan Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
Qianjiang Yongan Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 8% to 1%.
Qianjiang Yongan Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 1%.
Qianjiang Yongan Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
Qianjiang Yongan Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
Qianjiang Yongan Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Qianjiang Yongan Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Qianjiang Yongan Pharmaceutical Co Ltd's Revenue has dropped by 27% over the past 12 months.
Qianjiang Yongan Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.02.
Qianjiang Yongan Pharmaceutical Co Ltd's short-term assets (1B CNY) exceed its short-term liabilties (263m CNY).
Qianjiang Yongan Pharmaceutical Co Ltd's long-term assets (2B CNY) exceed its long-term liabilties (382m CNY).
Qianjiang Yongan Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (919m CNY) than debt (40m CNY).
Qianjiang Yongan Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 5.87.
Valuation Backtest
Qianjiang Yongan Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Qianjiang Yongan Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Qianjiang Yongan Pharmaceutical Co Ltd
Balance Sheet Decomposition
Qianjiang Yongan Pharmaceutical Co Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 919m |
| Receivables | 186.5m |
| Other Current Assets | 105.8m |
| Non-Current Assets | 1.2B |
| Long-Term Investments | 113.4m |
| PP&E | 994.2m |
| Intangibles | 92m |
| Other Non-Current Assets | 14.3m |
| Current Liabilities | 263.2m |
| Accounts Payable | 123.3m |
| Accrued Liabilities | 35.6m |
| Short-Term Debt | 40.2m |
| Other Current Liabilities | 64.1m |
| Non-Current Liabilities | 119m |
| Other Non-Current Liabilities | 119m |
Earnings Waterfall
Qianjiang Yongan Pharmaceutical Co Ltd
|
Revenue
|
1.1B
CNY
|
|
Cost of Revenue
|
-758.9m
CNY
|
|
Gross Profit
|
383.3m
CNY
|
|
Operating Expenses
|
-359.9m
CNY
|
|
Operating Income
|
23.3m
CNY
|
|
Other Expenses
|
1.8m
CNY
|
|
Net Income
|
25.1m
CNY
|
Free Cash Flow Analysis
Qianjiang Yongan Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Qianjiang Yongan Pharmaceutical Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Qianjiang Yongan Pharmaceutical Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Qianjiang Yongan Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Qianjiang Yongan Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Qianjiang Yongan Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Qianjiang Yongan Pharmaceutical Co Ltd
is 18.9 CNY
.
Shareholder Return
Price
Qianjiang Yongan Pharmaceutical Co Ltd
| Average Annual Return | -1.28% |
| Standard Deviation of Annual Returns | 13.01% |
| Max Drawdown | -65% |
| Market Capitalization | 2B CNY |
| Shares Outstanding | 287 411 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Qianjiang Yongan Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the research, development, production and sales of taurine products. The company is headquartered in Qianjiang, Hubei and currently employs 927 full-time employees. The company went IPO on 2010-03-05. The firm operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.
Contact
IPO
Employees
Officers
The intrinsic value of one
Qianjiang Yongan Pharmaceutical Co Ltd
stock under the Base Case scenario is
7.47
CNY.
Compared to the current market price of 6.9 CNY,
Qianjiang Yongan Pharmaceutical Co Ltd
is
Undervalued by 8%.
You don't have any saved screeners yet
